| 1 |
35112552 | Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001). | 2022 Feb 3 |
2 |
| 2 |
35170195 | Long noncoding RNA CCAT2 reduces chemosensitivity to 5-fluorouracil in breast cancer cells by activating the mTOR axis. | 2022 Mar |
1 |
| 3 |
35176419 | p70 S6 kinase as a therapeutic target in cancers: More than just an mTOR effector. | 2022 Jun 1 |
1 |
| 4 |
35379887 | Multi-site desmoplastic small round cell tumors are genetically related and immune-cold. | 2022 Apr 4 |
1 |
| 5 |
33073679 | mTOR Inhibition Ablates Cisplatin-Resistant Salivary Gland Cancer Stem Cells. | 2021 Apr |
1 |
| 6 |
33107222 | Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma. | 2021 Jan |
1 |
| 7 |
33159216 | A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors. | 2021 Mar |
1 |
| 8 |
33479203 | Survival of salivary gland cancer stem cells requires mTOR signaling. | 2021 Jan 21 |
1 |
| 9 |
33638305 | A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies. | 2021 Mar |
1 |
| 10 |
34057619 | Analysis of the Correlation between CD133 Expression on Human Colorectal Adenocarcinoma Cells HT-29 and Their Resistance to Chemotherapeutic Drugs. | 2021 May |
1 |
| 11 |
34216687 | PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition. | 2021 Nov 1 |
1 |
| 12 |
34310349 | Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors. | 2021 Sep 1 |
1 |
| 13 |
34320785 | Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. | 2021 Jul 29 |
1 |
| 14 |
34331013 | Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss. | 2021 Sep |
1 |
| 15 |
34565342 | Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma. | 2021 Sep 26 |
1 |
| 16 |
34589671 | The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial. | 2021 Oct |
1 |
| 17 |
34950179 | Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling. | 2021 Nov |
1 |
| 18 |
31862477 | Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. | 2020 Feb |
2 |
| 19 |
31960523 | ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer. | 2020 Mar |
1 |
| 20 |
32057715 | A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer. | 2020 Jun |
1 |
| 21 |
32209188 | [Apatinib Combined with CCI-779 Inhibits the Proliferation and Migration of Small Cell Lung Cancer NCI-H446 Cells In Vitro]. | 2020 Apr 20 |
3 |
| 22 |
32232883 | Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma. | 2020 May |
1 |
| 23 |
33489922 | The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside. | 2020 |
1 |
| 24 |
30125350 | Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells. | 2019 Mar 15 |
1 |
| 25 |
30733891 | Mantle cell lymphoma and its management: where are we now? | 2019 |
1 |
| 26 |
30866995 | A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors. | 2019 Mar 12 |
2 |
| 27 |
30918329 | Identification and characterization of two novel oncogenic mTOR mutations. | 2019 Jun |
1 |
| 28 |
31059051 | The combination of temsirolimus and chloroquine increases radiosensitivity in colorectal cancer cells. | 2019 Jul |
3 |
| 29 |
31253398 | Temsirolimus as a dual inhibitor of retinoblastoma and angiogenesis via targeting mTOR signalling. | 2019 Aug 27 |
2 |
| 30 |
31398711 | The role of mTOR pathway as target for treatment in adrenocortical cancer. | 2019 Sep |
1 |
| 31 |
31410178 | Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas. | 2019 Sep |
1 |
| 32 |
31570436 | Low-dose Docetaxel Enhanced the Anticancer Effect of Temsirolimus by Overcoming Autophagy in Prostate Cancer Cells. | 2019 Oct |
2 |
| 33 |
31588998 | PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer. | 2019 Oct 7 |
1 |
| 34 |
31695068 | Genetic deletion of S6k1 does not rescue the phenotypic deficits observed in the R6/2 mouse model of Huntington's disease. | 2019 Nov 6 |
2 |
| 35 |
28263222 | mTOR and Cardiovascular Diseases: Diabetes Mellitus. | 2018 Feb |
1 |
| 36 |
29313954 | Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. | 2018 Apr 1 |
1 |
| 37 |
29408183 | Invasive pulmonary aspergillosis mimicking organizing pneumonia after mTOR inhibitor therapy: A case report. | 2018 Apr |
2 |
| 38 |
29484131 | Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma. | 2018 Jan 26 |
1 |
| 39 |
29508857 | Targeting the PI3K pathway in cancer: are we making headway? | 2018 May |
1 |
| 40 |
29668485 | Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: a case report and literature review. | 2018 Jul |
1 |
| 41 |
29721158 | Acquired resistance to temsirolimus is associated with integrin α7 driven chemotactic activity of renal cell carcinoma in vitro. | 2018 Apr 10 |
1 |
| 42 |
30299205 | Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer. | 2018 |
1 |
| 43 |
30357890 | Synthesis and anticancer activity of novel rapamycin C-28 containing triazole moiety compounds. | 2018 Nov |
1 |
| 44 |
30410720 | A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas. | 2018 |
1 |
| 45 |
30488350 | Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study. | 2018 Dec |
1 |
| 46 |
30510618 | Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges. | 2018 |
1 |
| 47 |
27526062 | Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model. | 2017 Feb |
1 |
| 48 |
27737762 | CB1 Cannabinoid Receptors Mediate Cognitive Deficits and Structural Plasticity Changes During Nicotine Withdrawal. | 2017 Apr 1 |
1 |
| 49 |
27893038 | Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. | 2017 Apr 1 |
1 |
| 50 |
28000286 | Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group. | 2017 May |
2 |